Learning gene networks underlying clinical phenotypes using SNP perturbation
- Availability of genome sequence, molecular, and scientific phenotype information for big affected person cohorts generated by current technological advances supplies a chance to dissect the genetic structure of advanced illnesses at system stage. Nevertheless, earlier analyses of such information have largely targeted on the co-localization of SNPs related to scientific and expression traits, every recognized from genome-wide affiliation research and expression quantitative trait locus mapping.
- Thus, their description of the molecular mechanisms behind the SNPs influencing scientific phenotypes was restricted to the one gene linked to the co-localized SNP. Right here we introduce PerturbNet, a statistical framework for studying gene networks that modulate the affect of genetic variants on phenotypes, utilizing genetic variants as naturally occurring perturbation of a organic system. PerturbNet makes use of a probabilistic graphical mannequin to straight mannequin the cascade of perturbation from genetic variants to the gene community to the phenotype community together with the networks at every layer of the organic system.
- PerturbNet learns the whole mannequin by fixing a single optimization drawback with an environment friendly algorithm that may analyze human genome-wide information inside a couple of hours. PerturbNet inference procedures extract an in depth description of how the gene community modulates the genetic results on phenotypes. Utilizing simulated and bronchial asthma information, we exhibit that PerturbNet improves statistical energy for detecting disease-linked SNPs and identifies gene networks and community modules mediating the SNP results on traits, offering deeper insights into the underlying molecular mechanisms.
Identification of strong genes in transcriptional regulatory community of Mycobacterium tuberculosis
About 30% of the world inhabitants is contaminated with Mycobacterium tuberculosis (MTB). It’s well-known that the gene expression in MTB is very variable, thus screening of conventional single-gene in MTB has been incapable to satisfy the wishes of scientific analysis. On this report, the authors systemically analysed the transcription regulatory community (TRN) in MTB H37Rv.
The advanced interaction of those gene interactions has been revealed utilizing exhaustive topological and world evaluation of TRN utilizing parameters together with indegree, outdegree, diploma, directed and undirected common path size (APL), and randomly carried out.
Outcomes from indegree evaluation reveal a set of essential genes, together with papA5 and Rv0177 that are related to excessive indegree values. Gene ontology evaluation prompt their significance within the virulence of MTB. As well as, APL and evaluation of extremely important genes additional recognized some essential genes with completely different APL values.
Among the many listing of genes recognized, the csoR gene has the shortest directed APL rating and excessive outdegree worth, thus suggesting their significance in sustaining community topology. This examine supplies a complete evaluation of TRN and gives foundation of understanding for growing experimental examine looking for new therapeutic targets towards MTB H37Rv pathogen.
Syndecan-1 and KRAS Gene Expression Signature Associates With Affected person Survival in Pancreatic Most cancers
Targets: The aim of this examine was to research the affiliation of syndecan-1 (SDC1) and KRAS molecular traits with affected person survival in pancreatic most cancers.
Strategies: Each SDC1 mRNA and methylation and KRAS mRNA and somatic mutations, in addition to scientific information have been retrieved from a The Most cancers Genome Alta pancreatic most cancers information set for survival analyses. Kyoto Encyclopedia of Gene and Genomes pathway evaluation for coexpressed genes for both SDC1 or KRAS was carried out, respectively.
Outcomes: A considerably adverse correlation existed between SDC1 mRNA and DNA methylation. Sufferers with KRAS somatic mutations had a considerably greater SDC1 mRNA however decrease methylation than these with out the mutations. In contrast with sufferers with KRASSDC1 signature, these with a excessive stage of KRAS and SDC1 alone or each had a considerably elevated mortality. The adjusted hazard ratios (95% confidence interval) have been 2.30 (1.16-4.54, P = 0.017) for KRASSDC1, 2.85 (1.48-5.49, P = 0.002) for KRASSDC1, and a pair of.48 (1.31-4.70, P = 0.005) for KRASSDC1, respectively. A number of Kyoto Encyclopedia of Gene and Genomes pathways have been shared, whereas there have been distinct pathways between KRAS and SDC1 coexpressed genes.
Conclusions: SDC1 interplays with KRAS, and concentrating on each KRAS and SDC1 together could also be extra helpful to pancreatic most cancers sufferers.
Brief communication: Genome-wide identification of latest reference genes for reverse-transcription quantitative PCR in Streptococcus thermophilus primarily based on RNA-sequencing evaluation
Streptococcus thermophilus, probably the most essential industrial lactic acid micro organism, is extensively used for the manufacturing of fermented dairy merchandise akin to yogurt and cheese. The accuracy of gene expression-based analyses (e.g., reverse-transcription quantitative real-time PCR) depends closely on the choice of dependable reference genes (RG), which supplies the idea for appropriately decoding expression information. Nevertheless, many conventional RG are usually not stably expressed in several techniques.
Right here we used RNA-sequencing to systematically examine gene expression variation on the genome scale and establish extra steady RG in S. thermophilus. In whole, 21 putative candidate RG have been recognized with variation coefficient values <10.Zero primarily based on the expression of all 1,911 genes underneath Four completely different experimental situations.
We chosen and validated 12 RG chosen from transcriptomes through the use of reverse-transcription quantitative real-time PCR, and ranked their expression stability by statistical algorithms geNorm and NormFinder. In contrast with conventional RG 16S rRNA, genes encoding glycine-tRNA ligase subunit β GlyS and fatty acid-binding protein DegV have been extra steady underneath all Four remedies, which have by no means been used as RG in S. thermophilus. Our discovering supplies the inspiration for extra exact evaluation of gene expression in S. thermophilus and different lactic acid micro organism species.
Insights into the genetic range, recombination, and systemic infections with proof of intracellular maturation of hepadnavirus in cats
- Hepatitis B virus (HBV) is a human pathogen of world concern, whereas a excessive range of viruses associated to HBV have been found in different animals over the past decade. Not too long ago, the novel mammalian hepadnavirus, tentatively named home cat hepadnavirus (DCH), was detected in an immunocompromised cat.
- Herein, a group of 209 cat sera and 15 hepato-diseased cats have been screened for DCH utilizing PCR, leading to 12.4% and 20% positivity within the examined sera and necropsied cats, respectively. Among the many DCH-positive sera, a considerably excessive stage of co-detection with retroviral an infection was discovered, with the best proportion being co-detection with feline immunodeficiency virus (FIV). Full-length genome characterization of DCH revealed the genetic range between the 9 Thai DCH sequences obtained, and that they phylogenetically shaped three distinct monophyletic clades.
- A putative DCH recombinant pressure was discovered, suggesting a potential position of recombination in DCH evolution. Moreover, quantitative PCR was used to find out the viral copy quantity in varied organs of the DCH-moribund cats, whereas the pathological findings have been in comparison with the viral localization in hepatocytes, adjoining to areas of hepatic fibrosis, by immunohistochemical (IHC) and western blot evaluation.
- Along with the liver, positive-DCH immunoreactivity was present in varied different organs, together with kidneys, lung, coronary heart, gut, mind, and lymph nodes, offering proof of systemic an infection. Ultrastructure of contaminated cells revealed electron-dense particles within the nucleus and cytoplasm of hepatocytes, bronchial epithelial cells, and fibroblasts. We suggest the intracellular improvement mechanism of this virus. Though the definitive roles of pathogenicity of DCH stays undetermined, a contributory position of the virus related to systemic illnesses is feasible.
 HIV-1 p24 recombinant antigen |
|||
| 8909 | Virostat | 100 ug | EUR 608.1 |
|
Description: This is HIV-1 p24 recombinant antigen for ELISA,WB. |
|||
 HIV-P24 antigen array kit |
|||
| VArk-Lsx001 | Creative Biolabs | unit | Ask for price |
|
Description: Fourth-generation HIV immunoassays detect viral p24 protein in the blood. |
|||
 HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
 HIV 1 p24 core recombinant antigen |
|||
| 00177-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV 1 p24 core recombinant antigen. |
|||
HIV 1 p24 core recombinant antigen |
|||
| 00177-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV 1 p24 core recombinant antigen. |
|||
 HIV-1 p24 ELISA Kit |
|||
| Z7040001 | Biochain | 1 kit | EUR 974.4 |
|
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol. |
|||
 HIV-1 p24 |
|||
| E5-00024 | EnoGene | 1mg | EUR 1152 |
HIV-1 p24 |
|||
| E62H002 | EnoGene | 100ug | EUR 458.4 |
) HIV Type 1 p24 Antigen ELISA (96 Determinations) |
|||
| 0801111 | Zeptometrix | 96T | EUR 657.79 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
) HIV Type 1 p24 Antigen ELISA 2.0 (96 Determinations) |
|||
| 0801002 | Cusabio | 96T | EUR 657.79 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
 HIV type 1 P24 |
|||
| DAG1520 | Creative Diagnostics | 100 µg | EUR 972 |
 HIV-1 p24 Antibody |
|||
| 7313-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains. |
|||
HIV-1 p24 Antibody |
|||
| 7313-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains. |
|||
 Recombinant HIV-1 p24 |
|||
| 7-07603 | CHI Scientific | 100µg | Ask for price |
Recombinant HIV-1 p24 |
|||
| 7-07604 | CHI Scientific | 500µg | Ask for price |
Recombinant HIV-1 p24 |
|||
| 7-07605 | CHI Scientific | 1000µg | Ask for price |
 HIV-1 Gag p24 |
|||
| 05-005 | Sceti | 50 ug | EUR 434.4 |
|
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur. |
|||
HIV-1 Gag p24 |
|||
| 05-006 | Sceti | 250 ug | EUR 1154.4 |
|
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur. |
|||
 HIV-1, p24 Protein |
|||
| abx069857-1mg | Abbexa | 1 mg | EUR 1888.8 |
 HIV-1 p24 Protein |
|||
| abx169032-1mg | Abbexa | 1 mg | EUR 661.2 |
HIV-1 p24 Antibody |
|||
| 20-abx137062 | Abbexa |
|
|
HIV-1 p24 Antibody |
|||
| abx021869-1mg | Abbexa | 1 mg | EUR 794.4 |
HIV-1 p24 Antibody |
|||
| abx021870-1mg | Abbexa | 1 mg | EUR 760.8 |
HIV-1 p24 Antibody |
|||
| abx021871-1mg | Abbexa | 1 mg | EUR 794.4 |
HIV-1 p24 Antibody |
|||
| abx021872-1mg | Abbexa | 1 mg | EUR 794.4 |
HIV-1 p24 Antibody |
|||
| abx021873-1mg | Abbexa | 1 mg | EUR 794.4 |
HIV-1 p24 Antibody |
|||
| abx021882-1mg | Abbexa | 1 mg | EUR 1178.4 |
HIV-1 p24 Antibody |
|||
| abx021883-1mg | Abbexa | 1 mg | EUR 1220.4 |
HIV-1 p24 Antibody |
|||
| abx021886-1mg | Abbexa | 1 mg | EUR 1220.4 |
HIV-1 p24 Antibody |
|||
| abx021887-1mg | Abbexa | 1 mg | EUR 1220.4 |
HIV-1 p24 Antibody |
|||
| abx021888-1mg | Abbexa | 1 mg | EUR 1220.4 |
HIV-1 p24 Antibody |
|||
| abx023027-1ml | Abbexa | 1 ml | EUR 693.6 |
 HIV 1 p24 Protein |
|||
| abx060589-1mg | Abbexa | 1 mg | EUR 1545.6 |
HIV-1 p24 Protein |
|||
| abx061424-05mg | Abbexa | 0.5 mg | EUR 886.8 |
HIV-1 p24 Antibody |
|||
| abx023925-1mg | Abbexa | 1 mg | EUR 828 |
HIV-1 p24 Antibody |
|||
| abx023926-1mg | Abbexa | 1 mg | EUR 828 |
HIV-1 p24 Protein |
|||
| 20-abx261886 | Abbexa |
|
|
 Antibody) p24-HIV(p24/661) Antibody |
|||
| BNCA0661-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against p24-HIV(p24/661), APC conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNCAP0661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNCAP0661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC610661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF660R conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC610661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF660R conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNCR0661-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against p24-HIV(p24/661), RPE conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNUB0661-100 | Biotium | 100uL | EUR 250.8 |
|
Description: Primary antibody against p24-HIV(p24/661), Concentration: 0.2mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNUB0661-500 | Biotium | 500uL | EUR 549.6 |
|
Description: Primary antibody against p24-HIV(p24/661), Concentration: 0.2mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC430661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF543 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC430661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF543 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC400661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC400661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC880661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC880661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC810661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC810661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNCH0661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNCH0661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNCP0661-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against p24-HIV(p24/661), PerCP conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNUM0661-50 | Biotium | 50uL | EUR 474 |
|
Description: Primary antibody against p24-HIV(p24/661), 1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC050661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC050661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC680661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF568 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC680661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF568 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC700661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC700661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC800661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC800661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNCB0661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), Biotin conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNCB0661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), Biotin conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC940661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC940661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC550661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF555 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC550661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF555 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC470661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF647 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC470661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF647 conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC040661-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL |
|||
p24-HIV(p24/661) Antibody |
|||
| BNC040661-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL |
|||
 HIV p24 Antibody |
|||
| abx021867-1mg | Abbexa | 1 mg | EUR 1612.8 |
HIV p24 Antibody |
|||
| abx021868-1mg | Abbexa | 1 mg | EUR 1612.8 |
) Human(HIV-P24) |
|||
| QY-E05679 | Qayee Biotechnology | 96T | EUR 433.2 |
) HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations) |
|||
| 0801200 | Zeptometrix | 5 X 96T | EUR 2543.52 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
 Custom Antibody titration by ELISA up to 2 rabbits and 1 bleed |
|||
| ELISA-1 | Alpha Diagnostics | 1 | EUR 242.4 |
 HIV type 1 P24 [His] |
|||
| DAG2375 | Creative Diagnostics | 100 µg | EUR 868.8 |
HIV type 1 P24 [His] |
|||
| DAG2377 | Creative Diagnostics | 100 µg | EUR 868.8 |
 HIV type 1 p24 [FITC] |
|||
| DAGH004 | Creative Diagnostics | 50 Tests | EUR 1112.4 |
 HIV type 1 P24 [GST] |
|||
| DAG1516 | Creative Diagnostics | 100 µg | EUR 774 |
HIV type 1 P24 [His] |
|||
| DAG1518 | Creative Diagnostics | 100 µg | EUR 774 |
 HIV type 1 P24 [Biotin] |
|||
| DAG1519 | Creative Diagnostics | 100 µg | EUR 972 |
HIV type 1 P24 [His] |
|||
| DAG1799 | Creative Diagnostics | 50 ug | EUR 2017.2 |
 HIV-1 p24 Recombinant Protein |
|||
| 53-341 | ProSci | 0.01 mg | EUR 789.9 |
|
Description: HIV-1 p24 Recombinant Protein |
|||
 Recombinant HIV-1 p24 Core |
|||
| 7-07597 | CHI Scientific | 100µg | Ask for price |
Recombinant HIV-1 p24 Core |
|||
| 7-07598 | CHI Scientific | 500µg | Ask for price |
Recombinant HIV-1 p24 Core |
|||
| 7-07599 | CHI Scientific | 1000µg | Ask for price |
 Recombinant HIV-1 p24 , 24kDa |
|||
| 7-07621 | CHI Scientific | 2µg | Ask for price |
Recombinant HIV-1 p24 , 24kDa |
|||
| 7-07622 | CHI Scientific | 10µg | Ask for price |
